Published in Ann N Y Acad Sci on March 01, 2003
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
DNA methylation as a universal biomarker. Expert Rev Mol Diagn (2010) 1.18
The ghost in our genes: legal and ethical implications of epigenetics. Health Matrix Clevel (2009) 0.97
Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics (2008) 0.91
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
MethyQA: a pipeline for bisulfite-treated methylation sequencing quality assessment. BMC Bioinformatics (2013) 0.89
Cytostatic drug treatment causes seeding of gene promoter methylation. Eur J Cancer (2007) 0.80
Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38α as a novel candidate for resistance. Pharmacol Res Perspect (2016) 0.75
Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors. Mol Oncol (2017) 0.75
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet (2012) 3.07
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology (2010) 2.54
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47
The functional consequences of alternative promoter use in mammalian genomes. Trends Genet (2008) 2.47
Health risk of chrysotile revisited. Crit Rev Toxicol (2013) 2.45
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43
T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem (2006) 2.24
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res (2005) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A (2010) 1.83
Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis (2005) 1.77
CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol (2008) 1.66
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res (2011) 1.58
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
DNA methylation of the Trip10 promoter accelerates mesenchymal stem cell lineage determination. Biochem Biophys Res Commun (2010) 1.52
Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Res (2004) 1.50
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. Prostate (2014) 1.46
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature. Arch Pathol Lab Med (2012) 1.46
Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut (2010) 1.44
Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol (2009) 1.41
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther (2005) 1.40
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol (2013) 1.38
Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res (2009) 1.37
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
High resolution detection and analysis of CpG dinucleotides methylation using MBD-Seq technology. PLoS One (2011) 1.35
Recommendations for improved acute pain services: Canadian collaborative acute pain initiative. Pain Res Manag (2004) 1.33
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res (2008) 1.33
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat (2004) 1.32
Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res (2008) 1.30
Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J Biol Chem (2005) 1.30
MPromDb: an integrated resource for annotation and visualization of mammalian gene promoters and ChIP-chip experimental data. Nucleic Acids Res (2006) 1.28
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
Improved validation of peptide MS/MS assignments using spectral intensity prediction. Mol Cell Proteomics (2006) 1.28
DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology (2013) 1.28
Toward a human epigenome. Nat Genet (2006) 1.28
Methods in DNA methylation profiling. Epigenomics (2009) 1.25
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Spirometry testing standards in spinal cord injury. Chest (2003) 1.22
Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species. Proc Natl Acad Sci U S A (2012) 1.22
Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods (2002) 1.21
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20
Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res (2010) 1.18
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest (2010) 1.17
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis (2005) 1.17
Profiling DNA methylomes from microarray to genome-scale sequencing. Technol Cancer Res Treat (2010) 1.17
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
Differential methylation hybridization: profiling DNA methylation with a high-density CpG island microarray. Methods Mol Biol (2009) 1.15
The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer (2009) 1.15
Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res (2011) 1.15
The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res (2004) 1.15
Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis (2008) 1.15
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res (2011) 1.13
Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res (2010) 1.12
Genome-wide mapping of RNA Pol-II promoter usage in mouse tissues by ChIP-seq. Nucleic Acids Res (2010) 1.10
Genome screen to detect linkage to intracranial aneurysm susceptibility genes: the Familial Intracranial Aneurysm (FIA) study. Stroke (2008) 1.10
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell (2013) 1.09